Tue, 04 Aug 2020

Hemogenyx Pharmaceuticals PLC Announces Grant of Options

14 Jul 2020, 01:09 GMT+10

LONDON, UK / ACCESSWIRE / July 13, 2020 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)('Hemogenyx Pharmaceuticals' or the 'Company'), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the Board of Directors has agreed to grant options over a total of 6,200,626 ordinary shares of 1p each in the capital of the Company ('Share Options') to certain PDMRs and a member of the Scientific Advisory Board of the Company.

The details of the Share Options granted are set out below:

Following the grant of the Share Options, in aggregate there will be 36,753,702 ordinary shares of 1p each of the Company under option to directors, employees and members of the Scientific Advisory Board of the Company, representing 8.48% of the issued ordinary share capital of the Company.


Notification and public disclosure of transactions by persons discharging managerial responsibilities ('PDMR') and persons closely associated with them ('PCA'):


Aggregated information

- Aggregated volume

- Price


Date of the transaction



Place of the transaction

Outside of a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View source version on accesswire.com:

Sign up for Denver News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!